Document is current
Any future updates will be listed below
-
Authors
Chan, Oi Man
Xu, Wenye
Cheng, Nam Sze
Leung, Agnes Sze Yin
Ching, Jessica Yuet Ling
Fong, Brian Leong Yuen
Cheong, Pui Kuan
Zhang, Lin
Chan, Francis Ka Leung
Ng, Siew Chien
Leung, Ting Fan
- License Information
-
More Information
Article History
Received: 14 September 2023
Accepted: 6 February 2024
First Online: 7 February 2024
Competing interests
: FKLC is Board Member of CUHK Medical Centre. He is a co-founder, non-executive Board Chairman and shareholder of GenieBiome Ltd. He receives patent royalties through his affiliated institutions. He has received fees as an advisor and honoraria as a speaker for Eisai, AstraZeneca, Pfizer, Takeda, and Takeda (China) Holdings. SCN has served as an advisory board member for Pfizer, Ferring, Janssen, and Abbvie and received honoraria as a speaker for Ferring, Tillotts, Menarini, Janssen, Abbvie and Takeda. SCN has received research grants through her affiliated institutions from Olympus, Ferring, and Abbvie. SCN is a scientific co-founder and shareholder of GenieBiome Ltd. SCN receives patent royalties through her affiliated institutions. FKLC and SCN are named inventors of patent applications held by the CUHK that cover the therapeutic use of SIM03. FKLC, SCN and LZ are named inventors of patent application held by the CUHK and/or MagIC that cover the therapeutic and diagnostic use of microbiome.
